Phaseline

Companies › Linnaeus Therapeutics

Linnaeus Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Feb 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LNS8801
G protein-coupled estrogen receptor (GPER) agonist
GPERPhase 2Melanoma (Skin Cancer); Solid Tumor, AdultFeb 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04130516LNS8801Phase 1Solid Tumor, AdultOncologyJun 2026
NCT06624644LNS8801Phase 2Melanoma (Skin Cancer)OncologyFeb 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

GPER (1)

Companies with the same targets

–

Companies built like this

Vasgene Therapeutics Suzhou BlueHorse Therapeutics Pieris Pharmaceuticals Evaxion Biotech Primmune Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.